{"success":true,"data":{"pressRelease":{"id":"50263","rtpr_id":"nWkr7bhFB7","ticker":"PMED","exchange":"","all_tickers":["PMED"],"title":"The subscription price for warrants of series TO6 in Peptonic has been determined to SEK 0.0011 and the exercise period begins today","author":"Cision","published_at":"2026-06-01T06:30:07.745Z","article_body":"PEPTONIC Medical AB\n\nNOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR\nTO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH\nAFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION\nOF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND\nTHOSE REQUIRED BY SWEDISH LAW.\nPeptonic Medical AB (\"Peptonic\" or the \"Company\") completed during the first\nquarter of 2026 a rights issue of units, consisting of shares and warrants of\nseries TO6 (the \"Warrants\" or “TO6”). The subscription price for the\nWarrants has been determined to SEK 0.0011 per share, which corresponds to 70\npercent of the volume-weighted average price in the Company's share on\nSpotlight Stock Market during the measurement period, which ran from May 18,\n2026, up to and including May 29, 2026. One (1) Warrant entitles the holder to\nsubscribe for one (1) new share in the Company from today, June 1, 2026, up to\nand including June 12, 2026.\n\nToday, June 1, 2026, the exercise period for TO6 begins. Each TO6 entitles the\nholder to subscribe for one (1) new share in the Company at a subscription\nprice of SEK 0.0011. The subscription price for the Warrants corresponds to 70\npercent of the volume-weighted average price in the Company's share on\nSpotlight Stock Market during the measurement period, which ran from May 18,\n2026, up to and including May 29, 2026. Full terms and conditions for TO6 are\navailable on the Company's website: www.peptonicmedical.se.\n\nIf all TO6 are exercised, the Company will receive approximately SEK 12.5\nmillion before issuance costs. To avoid the TO6 expiring without value, it is\nrequired that the holder actively exercise TO6 to subscribe for new shares in\nthe Company no later than June 12, 2026, or dispose of the Warrants no later\nthan June 9, 2026. Please note that certain nominees may close their\nsubscription process earlier than June 12, 2026.\n\n \n\nThe outcome of the exercise of the Warrants is intended to be announced via a\npress release on or about June 15, 2026.\n\n \n\nSummarized terms for TO6:\n\nExercise period: June 1, 2026 – June 12, 2026.\n\nIssue size: 11,387,158,200 TO6, which entitles to subscription of\n11,387,158,200 shares. If all TO6 are exercised, the Company will receive\napproximately SEK 12.5 million before issuance costs.\n\nExercise price: SEK 0.0011 per share.\n\nLast day for trading in TO6: June 9, 2026.\n\nShare capital and dilution: If all TO6 are exercised the share capital will\nincrease with approximately SEK 1,138,715.8200, from approximately SEK\n2,072,456.7314 to approximately SEK 3,211,172.5514. If all TO6 are exercised\nthe number of shares in the Company will increase with 11,387,158,200 shares,\nfrom 20,724,567,314 shares to 32,111,725,514 shares. If all TO6 are exercised,\nthe dilution amounts to approximately 35.46 percent of the existing number of\nshares and votes in the Company.\n\n \n\nPlease note that TO6 that are not exercised on or before June 12, 2026, or\ndisposed of on or before June 9, 2026, will expire without value. For TO6 not\nto expire without value, the holder must actively subscribe for shares by\nexercise of the Warrants, or alternatively dispose of the Warrants.\n\n \n\nHow TO6 are exercised:\n\nNominee-registered TO6 (Custody account)\n\nSubscription and payment by exercise of TO6 shall be made in accordance with\ninstructions from each nominee. Please contact your nominee for additional\ninformation.\n\n \n\nDirect-registered TO6 (Securities account)\n\nNo issue statement or payment instructions will be sent out. Subscriptions\nwill be made through simultaneous payment in accordance with the instructions\non the application form. TO6 will then be replaced by interim shares awaiting\nregistration at the Swedish Companies Registration Office.\n\n \n\nThe application form including instructions for payment will be available at\nthe Company’s website, www.peptonicmedical.se, and on Mangold Fondkommission\nAB’s website, www.mangold.se.\n\n \n\nAdvisers\n\nMangold Fondkommission AB is financial adviser and Eversheds Sutherland\nAdvokatbyrå AB is legal adviser to Peptonic in connection with the\nutilization of TO6.\n\n \n\nFor further information, please contact:\n\nDaniel Rudeklint, interim CEO Peptonic Medical AB\n\nEmail: daniel.rudeklint@peptonicmedical.se\nPhone: +46 73 158 02 73\n\n \n\nAbout PEPTONIC medical AB\n\nPeptonic Medical AB (publ) is a Swedish medical technology company that\ndevelops and sells clinically proven self-care products in intimate women's\nhealth. Under the brands VagiVital and Vernivia, the Company offers an\nover-the-counter portfolio of effective and gentle products that help women\nunderstand, treat and prevent common medical conditions in the genital area.\nPeptonic's growth strategy is based on geographic expansion, especially in the\nUS and Europe, and on continuously strengthening the product portfolio through\nits own product development and strategic acquisitions.\n\n \n\nThe company is headquartered in Stockholm, Sweden, and has subsidiaries\nPeptonic Medical Inc. and Common Sense Marketing Inc. in the United States.\nPeptonic Medical was founded in 2009 and has been listed on the Spotlight\nStock Market since 2014.\n\n \n\nImportant information\n\nThe release, announcement or distribution of this press release may, in\ncertain jurisdictions, be subject to restrictions. The recipients of this\npress release in jurisdictions where this press release has been published or\ndistributed shall inform themselves of and follow such restrictions. The\nrecipient of this press release is responsible for using this press release,\nand the information contained herein, in accordance with applicable rules in\neach jurisdiction. This press release does not constitute an offer, or a\nsolicitation of any offer, to buy or subscribe for any securities in Peptonic\nin any jurisdiction, neither from Peptonic nor anyone else.\n\n \n\nThis press release does not constitute or form part of an offer or\nsolicitation to purchase or subscribe for securities in the United States. The\nsecurities referred to herein may not be sold in the United States absent\nregistration or an exemption from registration under the US Securities Act of\n1933, as amended (the “Securities Act”), and may not be offered or sold\nwithin the United States absent registration or an applicable exemption from,\nor in a transaction not subject to, the registration requirements of the\nSecurities Act. There is no intention to register any securities referred to\nherein in the United States or to make a public offering of the securities in\nthe United States. The information in this press release may not be announced,\npublished, copied, reproduced or distributed, directly or indirectly, in whole\nor in part, within or into Australia, Hong Kong, Japan, Canada, New Zealand,\nSwitzerland, South Africa, the United States, Belarus, Russia, or in any other\njurisdiction where such announcement, publication or distribution of the\ninformation would not comply with applicable laws and regulations or where\nsuch actions are subject to legal restrictions or would require additional\nregistration or other measures than what is required under Swedish law.\nActions taken in violation of this instruction may constitute a crime against\napplicable securities laws and regulations.\n\n \n\nhttps://news.cision.com/peptonic-medical-ab/r/the-subscription-price-for-warrants-of-series-to6-in-peptonic-has-been-determined-to-sek-0-0011-and-%2Cc4355584\n\n\n\n(c) Copyright Waymaker BIT News - Cision 2026","article_body_html":"","raw_payload":{"data":{"id":"nWkr7bhFB7","title":"The subscription price for warrants of series TO6 in Peptonic has been determined to SEK 0.0011 and the exercise period begins today","author":"Cision","ticker":"PMED","created":"2026-06-01T06:30:07.745Z","tickers":["PMED"],"exchange":"","article_body":"PEPTONIC Medical AB\n\nNOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR\nTO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH\nAFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION\nOF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND\nTHOSE REQUIRED BY SWEDISH LAW.\nPeptonic Medical AB (\"Peptonic\" or the \"Company\") completed during the first\nquarter of 2026 a rights issue of units, consisting of shares and warrants of\nseries TO6 (the \"Warrants\" or “TO6”). The subscription price for the\nWarrants has been determined to SEK 0.0011 per share, which corresponds to 70\npercent of the volume-weighted average price in the Company's share on\nSpotlight Stock Market during the measurement period, which ran from May 18,\n2026, up to and including May 29, 2026. One (1) Warrant entitles the holder to\nsubscribe for one (1) new share in the Company from today, June 1, 2026, up to\nand including June 12, 2026.\n\nToday, June 1, 2026, the exercise period for TO6 begins. Each TO6 entitles the\nholder to subscribe for one (1) new share in the Company at a subscription\nprice of SEK 0.0011. The subscription price for the Warrants corresponds to 70\npercent of the volume-weighted average price in the Company's share on\nSpotlight Stock Market during the measurement period, which ran from May 18,\n2026, up to and including May 29, 2026. Full terms and conditions for TO6 are\navailable on the Company's website: www.peptonicmedical.se.\n\nIf all TO6 are exercised, the Company will receive approximately SEK 12.5\nmillion before issuance costs. To avoid the TO6 expiring without value, it is\nrequired that the holder actively exercise TO6 to subscribe for new shares in\nthe Company no later than June 12, 2026, or dispose of the Warrants no later\nthan June 9, 2026. Please note that certain nominees may close their\nsubscription process earlier than June 12, 2026.\n\n \n\nThe outcome of the exercise of the Warrants is intended to be announced via a\npress release on or about June 15, 2026.\n\n \n\nSummarized terms for TO6:\n\nExercise period: June 1, 2026 – June 12, 2026.\n\nIssue size: 11,387,158,200 TO6, which entitles to subscription of\n11,387,158,200 shares. If all TO6 are exercised, the Company will receive\napproximately SEK 12.5 million before issuance costs.\n\nExercise price: SEK 0.0011 per share.\n\nLast day for trading in TO6: June 9, 2026.\n\nShare capital and dilution: If all TO6 are exercised the share capital will\nincrease with approximately SEK 1,138,715.8200, from approximately SEK\n2,072,456.7314 to approximately SEK 3,211,172.5514. If all TO6 are exercised\nthe number of shares in the Company will increase with 11,387,158,200 shares,\nfrom 20,724,567,314 shares to 32,111,725,514 shares. If all TO6 are exercised,\nthe dilution amounts to approximately 35.46 percent of the existing number of\nshares and votes in the Company.\n\n \n\nPlease note that TO6 that are not exercised on or before June 12, 2026, or\ndisposed of on or before June 9, 2026, will expire without value. For TO6 not\nto expire without value, the holder must actively subscribe for shares by\nexercise of the Warrants, or alternatively dispose of the Warrants.\n\n \n\nHow TO6 are exercised:\n\nNominee-registered TO6 (Custody account)\n\nSubscription and payment by exercise of TO6 shall be made in accordance with\ninstructions from each nominee. Please contact your nominee for additional\ninformation.\n\n \n\nDirect-registered TO6 (Securities account)\n\nNo issue statement or payment instructions will be sent out. Subscriptions\nwill be made through simultaneous payment in accordance with the instructions\non the application form. TO6 will then be replaced by interim shares awaiting\nregistration at the Swedish Companies Registration Office.\n\n \n\nThe application form including instructions for payment will be available at\nthe Company’s website, www.peptonicmedical.se, and on Mangold Fondkommission\nAB’s website, www.mangold.se.\n\n \n\nAdvisers\n\nMangold Fondkommission AB is financial adviser and Eversheds Sutherland\nAdvokatbyrå AB is legal adviser to Peptonic in connection with the\nutilization of TO6.\n\n \n\nFor further information, please contact:\n\nDaniel Rudeklint, interim CEO Peptonic Medical AB\n\nEmail: daniel.rudeklint@peptonicmedical.se\nPhone: +46 73 158 02 73\n\n \n\nAbout PEPTONIC medical AB\n\nPeptonic Medical AB (publ) is a Swedish medical technology company that\ndevelops and sells clinically proven self-care products in intimate women's\nhealth. Under the brands VagiVital and Vernivia, the Company offers an\nover-the-counter portfolio of effective and gentle products that help women\nunderstand, treat and prevent common medical conditions in the genital area.\nPeptonic's growth strategy is based on geographic expansion, especially in the\nUS and Europe, and on continuously strengthening the product portfolio through\nits own product development and strategic acquisitions.\n\n \n\nThe company is headquartered in Stockholm, Sweden, and has subsidiaries\nPeptonic Medical Inc. and Common Sense Marketing Inc. in the United States.\nPeptonic Medical was founded in 2009 and has been listed on the Spotlight\nStock Market since 2014.\n\n \n\nImportant information\n\nThe release, announcement or distribution of this press release may, in\ncertain jurisdictions, be subject to restrictions. The recipients of this\npress release in jurisdictions where this press release has been published or\ndistributed shall inform themselves of and follow such restrictions. The\nrecipient of this press release is responsible for using this press release,\nand the information contained herein, in accordance with applicable rules in\neach jurisdiction. This press release does not constitute an offer, or a\nsolicitation of any offer, to buy or subscribe for any securities in Peptonic\nin any jurisdiction, neither from Peptonic nor anyone else.\n\n \n\nThis press release does not constitute or form part of an offer or\nsolicitation to purchase or subscribe for securities in the United States. The\nsecurities referred to herein may not be sold in the United States absent\nregistration or an exemption from registration under the US Securities Act of\n1933, as amended (the “Securities Act”), and may not be offered or sold\nwithin the United States absent registration or an applicable exemption from,\nor in a transaction not subject to, the registration requirements of the\nSecurities Act. There is no intention to register any securities referred to\nherein in the United States or to make a public offering of the securities in\nthe United States. The information in this press release may not be announced,\npublished, copied, reproduced or distributed, directly or indirectly, in whole\nor in part, within or into Australia, Hong Kong, Japan, Canada, New Zealand,\nSwitzerland, South Africa, the United States, Belarus, Russia, or in any other\njurisdiction where such announcement, publication or distribution of the\ninformation would not comply with applicable laws and regulations or where\nsuch actions are subject to legal restrictions or would require additional\nregistration or other measures than what is required under Swedish law.\nActions taken in violation of this instruction may constitute a crime against\napplicable securities laws and regulations.\n\n \n\nhttps://news.cision.com/peptonic-medical-ab/r/the-subscription-price-for-warrants-of-series-to6-in-peptonic-has-been-determined-to-sek-0-0011-and-%2Cc4355584\n\n\n\n(c) Copyright Waymaker BIT News - Cision 2026"},"type":"article","timestamp":"2026-06-01T06:30:07.865905517Z","server_sent_at_ms":1780295407865},"received_at":"2026-06-01T06:30:07.940Z","source_url":"https://news.cision.com/peptonic-medical-ab/r/the-subscription-price-for-warrants-of-series-to6-in-peptonic-has-been-determined-to-sek-0-0011-and-%2Cc4355584"},"analysis":{"id":"39694","press_release_id":"50263","analysis_json":{"industry":{"label":"Health Care Equipment","sector":"Health Care"},"redFlags":["High dilution: ~35.5% increase in share count if warrants are fully exercised","Micro-cap volatility: Exercise price is extremely low (SEK 0.0011), indicating very low share price and potential listing compliance risks"],"eventType":"dilution","narrative":"Peptonic Medical AB announced the start of the exercise period for its TO6 warrants, allowing holders to subscribe for new shares at SEK 0.0011 per share.\n\nIf all 11.39 billion warrants are exercised, the company will raise approximately SEK 12.5 million, but existing shareholders will face a dilution of approximately 35.46%.\n\nThe exercise period runs from June 1 to June 12, 2026, with a final trading day for the warrants on June 9, 2026. Unexercised warrants will expire without value.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Massive 35% dilution event for Peptonic Medical as warrant exercise period opens."},"keyFigures":{"offeringPrice":0.0011,"sharesOffered":11387158200,"customDimensions":{"proceeds_sek":12500000,"existing_shares":20724567314,"dilution_percent":35.46,"post_exercise_shares":32111725514}},"quotedText":"If all TO6 are exercised, the dilution amounts to approximately 35.46 percent of the existing number of shares and votes in the Company.","namedEntities":{"people":[{"name":"Daniel Rudeklint","role":"interim CEO"}],"products":["VagiVital","Vernivia"],"companies":[{"name":"Peptonic Medical AB","ticker":"PMED","relationship":"filer"},{"name":"Mangold Fondkommission AB","relationship":"financial adviser"},{"name":"Eversheds Sutherland Advokatbyrå AB","relationship":"legal adviser"}],"dollarAmounts":[{"amount":"SEK 0.0011","context":"subscription price per share"},{"amount":"SEK 12.5 million","context":"proceeds from full exercise of warrants"},{"amount":"SEK 1,138,715.8200","context":"increase in share capital"},{"amount":"SEK 2,072,456.7314","context":"current share capital"},{"amount":"SEK 3,211,172.5514","context":"post-exercise share capital"}]},"materialImpact":{"score":4,"reasoning":"The exercise of warrants will result in approximately 35.46% dilution of existing shares if fully exercised. This exceeds the 20% threshold for high-impact dilution events, significantly impacting existing shareholders' ownership percentage."},"tickerRelevance":{"others":[],"primary":"PMED"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"high-dilution","sectorWeight":"low","householdBrandBoost":0,"marketCapAdjustment":"negative","retailFavoriteBoost":0}},"event_type":"dilution","event_type_secondary":null,"sentiment":"bearish","material_impact_score":4,"narrative":"Peptonic Medical AB announced the start of the exercise period for its TO6 warrants, allowing holders to subscribe for new shares at SEK 0.0011 per share.\n\nIf all 11.39 billion warrants are exercised, the company will raise approximately SEK 12.5 million, but existing shareholders will face a dilution of approximately 35.46%.\n\nThe exercise period runs from June 1 to June 12, 2026, with a final trading day for the warrants on June 9, 2026. Unexercised warrants will expire without value.","key_figures":{"offeringPrice":0.0011,"sharesOffered":11387158200,"customDimensions":{"proceeds_sek":12500000,"existing_shares":20724567314,"dilution_percent":35.46,"post_exercise_shares":32111725514}},"named_entities":{"people":[{"name":"Daniel Rudeklint","role":"interim CEO"}],"products":["VagiVital","Vernivia"],"companies":[{"name":"Peptonic Medical AB","ticker":"PMED","relationship":"filer"},{"name":"Mangold Fondkommission AB","relationship":"financial adviser"},{"name":"Eversheds Sutherland Advokatbyrå AB","relationship":"legal adviser"}],"dollarAmounts":[{"amount":"SEK 0.0011","context":"subscription price per share"},{"amount":"SEK 12.5 million","context":"proceeds from full exercise of warrants"},{"amount":"SEK 1,138,715.8200","context":"increase in share capital"},{"amount":"SEK 2,072,456.7314","context":"current share capital"},{"amount":"SEK 3,211,172.5514","context":"post-exercise share capital"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-01T06:30:31.363Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"high-dilution","sectorWeight":"low","householdBrandBoost":0,"marketCapAdjustment":"negative","retailFavoriteBoost":0}},"durationMs":23388,"modelName":"george-droid-qwen-72b"}}